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ABSTRACT 
Objective: The aim of the present study was to formulate the controlled release (CR) tablets of famotidine-cyclodextrin complexes to make the 
feasibility of complex in CR tablets and to access the kinetic of drug release mechanism 
Methods: In this work the solubility study of famotidine was performed in various solvents like 0.1 N HCl, phosphate buffer pH 7.4 and distilled 
water. Enhancement of the solubility and dissolution rate of famotidine was done by complexation with cyclodextrin before formulation into 
controlled release tablets. Tablets were prepared in different batches by using different concentration of HPMC K15M (hydroxy propyl methyl 
cellulose) and EC (ethyl cellulose) polymers and polymer blend. All batches were evaluated for pre-compression and post-compression parameters. 
Release kinetics was analyzed using zero order, first order, higuchi, peppas and hixon-crowell model. 
Results: All the formulation showed compliance with Pharmacopoeial standards. Release studies indicated that polymer blend (62%HPMCK15M and 
38%EC) based matrix tablets with complexed drug was able to control the release of famotidine up to 12 h. Optimized formulation F13 containing 
complexed drug with same polymer blend showed zero order release and the release mechanism was predominant matrix swelling with erosion. 
Conclusion: Results of the present study demonstrated that the drug: β-cyclodextrin complex would be a suitable candidate for preparing 
controlled release tablets of famotidine to improve drug solubility, flow properties and compressibility. Thus the complex used in matrix tablet is a 
promising approach to achieve appropriate controlled release dosage. 
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Recent research work was done on the development of new drug 
delivery system in compare to development of new molecules [1, 2] 
because development cost of new drug molecule is very high [3]. For 
oral administration poorly water soluble drugs require high doses to 
attain therapeutic plasma concentrations. Low water solubility is the 
major problem in formulation development of new drug. Hence, 
various techniques can be used to improve the solubility of poorly 
water soluble drugs as well as to improve its dissolution and 
bioavailability. Micronization, chemical modification, solid dispersion, 
complexation, co-solvency, hydrotropy and micellar solubilization 
techniques are used to improve the solubility of poorly soluble drugs. 
Cyclodextrin complexes play a very important role to enhance aqueous 
solubility and drug stability. Inclusion complex of poorly soluble drug 
with beta cyclodextrin increases the solubility in water and phosphate 
buffer also. Inclusion complexations are used to modify the physical 
and chemical properties of the drug molecule, in terms of water 
solubility [4, 5]. Thus cyclodextrin is interesting polymer in many 
fields, especially pharmaceutical applications. Inclusion complexes of 
cyclodextrin with hydrophobic molecules are able to penetrate body 
tissues [6]; these can be used to release drug compounds under 
specific conditions. Natural polymers are the first choice for 
formulation of hydrophilic matrix system, providing robust 
mechanism due to choice of viscosity grades, reproducible release 
profile, cost effectiveness and utilization of existing conventional 
equipment and methods. Water penetration, polymer swelling, drug 
dissolution, drug diffusion and matrix erosion from dosage form is 
controlled by the hydration of natural polymer, which forms the gel 
barrier through which the drug diffuses [7, 8]. Because of the 
flexibility, matrix systems are widely used in oral controlled drug 
delivery systems to obtain a desirable drug release profile and broad 
regulatory acceptance [9]. Famotidine is a potent H2 receptor 
antagonist used for treatment of heartburn, ulcers, and esophagitis at 
daily doses from 10 mg to 80 mg. Approved schedules of famotidine 
administration include 10 or 20 mg QD (‘quaque die’ means one a day) 
or BID (‘bis in die’ means twice a day) for treatment of heartburn, 20 
mg or 40 mg QD for healing ulcers, 20 mg BID (6 w) for treatment of 
gastroesophageal reflux disease and 20 or 40 mg BID for treatment of 
esophageal erosion. For treatment of Zollinger-Ellison Syndrome 
(hypersecretion of gastric acid), doses of up to 800 mg/day have been 
used. Famotidine has low water solubility (0.271 mg/ml). Therefore it 
requires multiple dosing for the treatment of gastric acid secretion for 
oral administration, which found to have many drawbacks, such as 
accumulation of drug in multidose therapy and poor patient 
compliance [10-12]. Controlled release formulations of famotidine can 
overcome some of these problems, while solubility enhancement 
increased bioavailability of famotidine [13, 14]. The present research 
work was aimed to attempt the complex of famotidine with β-
cyclodextrin by using kneading method and to evaluate by dissolution 
rate studies. Further it was confirmed by DSC (Differential Scanning 
calorimetry). Complex was used to formulate matrix tablets containing 
HPMC K15M and EC in different ratio. Optimization of formulations 
was done by dissolution studies. 
MATERIALS AND METHODS 
Materials 
The drug famotidine was obtained as a gift sample from Uniplus 
Biotech Ltd, Assoda, β-cyclodextrin was obtained from Albert David 
Pvt Ltd, Ghaziabad, India. HPMC K15 and EC were procured from 
Central drug house (P) LTD, New Delhi. All other chemicals and 
solvents used were of pharmaceutical and analytical grade. Double 
distilled water was used throughout the study for experimental work. 
Methods 
Preliminary study 
FTIR (Fourier transform infrared) spectroscopic study 
FTIR spectrum of famotidine was recorded using Perkin Elmer 
Instrument spectrum one (model) FTIR spectrometer and compared 
with reference spectra of pure drug, famotidine [10, 15]. 
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Equilibrium solubility study of pure drug 
Equilibrium solubility of the pure drug was determined in various 
solvents such as 0.1 N HCl, phosphate buffer pH 7.4 and distilled 
water. For this excess amount of drug was dissolved in solvent and 
kept for shaking at constant temperature for 72 h. Samples were 
collected at 24 h, 48 h and 72 h. Absorbance of the sample was 
measured by UV spectrophotometer and drug concentration was 
calculated at equilibrium state. 
DSC (Drug excipients compatibility) study 
Drug excipients compatibility study of pure drug was also performed 
to check the interaction of the pure drug with the polymers such as 
HPMC K15M, EC and β-cyclodextrin. For the estimation of drug-
polymer interaction, drug and polymer was mixed in 1:1, 1:0.50 and 
1:0.75 ratios and kept for study under controlled condition and it 
was examined by FTIR and DSC [15, 16]. 
Preparation of Famotidine, β-cyclodextrin inclusion complex  
It was prepared by kneading method [17, 18]. For this weigh 
famotidine and β-cyclodextrin in 1:1 molar ratio. Cyclodextrin was 
transferred to a glass mortar and small quantity of water: ethanol 
(1:1 v/v, 3 ml) solution was added to form a homogenous paste. 
Now the drug powder was slowly added to the paste and kneaded 
for 45 min. During the kneading process few drops of water was also 
added to maintain the consistency. The resultant paste was dried 
and grounded well followed by passing through 66 no. sieve. 
Prepared complex was stored in desiccator [19]. 
Characterization/Evaluation of prepared complex 
Dissolution rate studies 
Prepared complex were evaluated for drug release using USP 
apparatus II (LABINDIA). It was performed in 900 ml distilled water 
(pH 6.8), phosphate buffer (pH 7.4) and in 0.1 N HCl (pH 1.2) at 50 
rpm (revolution per minute). Temperature was maintained at 37 
°C±0.5 °C throughout the study. 5 ml of aliquots were withdrawn at 
fixed time interval and analyzed spectrophotometrically at 265 nm. 
Differential scanning calorimetry  
Differential scanning calorimetry (DSC) was performed by Perkin Elmer 
DSC 6000 to evaluate the prepared complex. DSC thermogram of 
complex was compared with DSC thermograms of pure drug and pure 
cyclodextrin. 
Formulation of controlled release tablets 
Controlled release matrix tablets were prepared by hydrophilic and 
hydrophobic polymer with complexed drug. For this all the 
ingredients were weighed according to formula given in table 1 and 
mixed well. Now the granules were formed by adding the binder 
solution to the powder and passed through the 66 no. sieve. 
Prepared granules were dried in hot air oven at 60 °C and again 
passed through same sieve followed by compression [20-22]. 
Pre-compression evaluation 
Various pre-compression parameters were evaluated for estimating 
the flow ability of powder. 
 
Table 1: Composition of controlled release tablets of famotidine 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 
Drug/Complex 130 130 130 130 130 130 130 270 270 270 270 270 270 
HPMC K15M - 65 97 130 15 47 80 65 97 130 15 47 80 
EC - - - - 50 50 50 - - - 50 50 50 
Magnesium stearate 10 10 10 10 10 10 10 10 10 10 10 10 10 
Talc 15 15 15 15 15 15 15 15 15 15 15 15 15 
PVP K30 15 15 15 15 15 15 15 15 15 15 15 15 15 
Lactose 330 265 233 200 265 233 200 125 93 60 125 93 60 
Total weight 500 500 500 500 500 500 500 500 500 500 500 500 500 
F1: Pure drug without polymers (HPMC K15M, EC), F2-F4: Containing pure drug and polymer (HPMC K15M in 1:0.5, 1:0.75, 1:1 ratio), F5-F7: 
Containing pure drug and polymer blend (HPMC K15M+EC in 1:0.5, 1:0.75, 1:1 ratio), F8-10: Containing famotidine-cyclodextrin complex 
equivalent to pure drug and polymer (HPMC K15M in 1:0.5, 1:0.75, 1:1 ratio), F11-F13: Containing famotidine-cyclodextrin complex equivalent to 
pure drug and polymer blend (HPMC K15M+EC in 1:0.5, 1:0.75, 1:1 ratio) 
 
Angle of repose 
Flow property of pure drug, drug: β-cyclodextrin complex and 





Where, θ = angle of repose, h= height of pile, r = radius of pile 
Bulk density [ρb] 
Bulk density of pure drug and prepared granules were determined 
by using the following formula:  
	




Tapped density [ρt] 
Tapped density of the drug powder and prepared granules was 
determined by using conventional tapping method using 10 ml 
cylinder with the help of following formula:  





Carr’s index or compressibility ratio of pure drug and prepared 
granules were calculated by using equation:  
Percentage compressibility =




Hausner’s ratio of drug powder and prepared granules were also 





Flow property of powder/granules on basis of various parameters 
was estimated according to the table 2. 
Post-compression evaluation 
Tablet thickness and diameter 
Thickness and diameter of the prepared tablets were measured by 
using the vernier calipers. 
Hardness testing 
Hardness of the prepared tablets was measured by using the 
monsanto hardness tester (Campbell electronics). Hardness of 
tablets may vary from 4 kg/cm2 to 8 kg/cm2. 
Friability 
Friability of the prepared tablets was determined by friability test 
apparatus (HICON New Delhi) by using the equation:  
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Percentage friability =  
Initial weight [Wi] − Final weight [Wf]
Initial weight [Wi]
× 100 
Friability limit for tablets is NMT (not more than) 0.4 % as per BP 
and NMT 8 % as per USP. 
Weight variation 
Weight variation of prepared tablets was determined by taking the 
average weight of 20 tablets and compared with weight variation 
tolerance for uncoated tablets. 
 
Table 2: Flow property and corresponding parameters 
Flow property  Parameters 
Angle of repose [ °] Hausner’s ratio Carr’s index [%] 
Excellent 25-30 1-1.11 <10 
Good 31-35 1.12-1.18 11-15 
Fair 36-40 1.19-1.25 16-20 
Passable 41-45 1.26-1.34 21-25 
Poor 46-55 1.35-1.45 26-31 
Very poor 56-65 1.46-1,59 32-37 
Very very poor >66 >1.60 >38 
 
Table 3: Weight variation tolerance for uncoated tablets 
Maximum % difference Average weight of tablets 
 IP/BP USP 
 10 <80 mg <130 mg 
 7.5 80 mg-250 mg 130 mg-324 mg 
 5 >250 mg >324 mg 
 
Content uniformity of drug 
Content uniformity of the tablet was analyzed by taking the drug in 
suitable diluents medium (phosphate buffer pH 7.4) and 
determining the absorbance of the solution at 265 nm. Drug content 
was calculated by using equation:  
Drug content 
=




Swelling index of the tablets was calculated by soaking the tablet in 
phosphate buffer pH 7.4 for two hours by using the equation:  
Swelling index =
Final weight [Wf] − Initial weight [Wi]
Final weight [Wf]
× 100 
In vitro dissolution studies 
Dissolution study of prepared tablets were carried out in USP 
dissolution apparatus II (LABINDIA) in 0.1 N HCl (pH 1.2) and 
phosphate buffer pH 7.4. Samples were withdrawn at specific time 
intervals and analyzed spectrophotometrically at 265 nm [22-24]. 
The amount of drug release was calculated by using the equation:  
Percentage drug release =
C × DF × V
Wa × 1000
× 100  
Where, C = concentration, DF = dilution factor, V = volume of 
dissolution medium,  
Wa = amount of drug 
Mechanism of drug release  
Drug release kinetic study was performed by various model 
dependent parameters, namely zero order, first order, Hixon-
crowell, korsemeyer and peppas etc. [25, 26]. 
• Zero order model 
A zero order release would be predicted by the equation  
Qt = Q0+K0t 
Where Qt = amount of drug dissolved in time t, Q0 = initial amount 
of the drug in solution, K0 = zero order release constant 
• First order model 
First order release was calculated by using equation:  
log C = log C0–Kt/2.303  
Where, C0 = initial concentration of drug, K = first order rate constant 
• Higuchi model 
Drug release from the matrix devices by diffusion has been 
described by equation:  
ft = Q = KH * t1/2 
Where, Q is Percentage of drug release at time t 
KH is Higuchi dissolution constant 
• Hixon-Crowell model 
Hixon and Crowell derived an equation for kinetic study in 1931. 
W01/3–Wt1/3 = κt 
Where, W0 is initial amount of drug in dosage form at time t 
Wt is remaining amount of drug in dosage form at time t 
Κ is surface volume relation constant 
• Korsmeyer-peppas model 
Korsmeyer derived a relationship which is used to describe drug release 
from a polymeric system. This relationship is described in equation:  
Mt/M∞ = Ktn 
Where, Mt/M∞ = fraction of drug released at time t 
K = release rate constant, n = release exponent 
Stability study 
Selected formulations were kept for 90 d in a stability chamber under 
controlled temperature and moisture. Temperature was kept 40±50 °C 
and humidity was maintained at 70±2 %. Samples were withdrawn at 0, 
30 and 90 d interval and evaluated for various parameters such as 
physical appearance (change in colour), absorption maxima and drug 
content. [16, 27]. All studies have been performed in triplicate. 
RESULTS AND DISCUSSION 
Preliminary studies 
FTIR spectroscopic study 
In FTIR spectra, strong bands were observed at 1638 cm-1, 1534 cm-
1, 1331 cm-1 and 1320 cm-1, which confirms the presence of imine, 
amine and sulfonyl group in the compound, as shown in fig. 1. Hence 
it proves the identity of pure drug. 
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Fig. 1: Observed FTIR spectra of pure drug (famotidine) 
 
Equilibrium solubility study of pure drug 
Equilibrium solubility of pure drug was determined in various 
solvents, such as 0.1 N HCl, phosphate buffer pH 7.4 and in 
distilled water by using UV spectrophotometer represented in 
table 4. Pure drug was found to be practically insoluble in 
distilled water as the solubility was found to be 69 µg/ml at 
equilibrium state. In 0.1 N HCl drug solubility was found to be 
780 µg/ml, which indicates that drug is highly soluble in acidic 
media. 
 
Table 4: Equilibrium solubility study of famotidine in different media 
Solvent Solubility (µg/ml) 
0.1 N HCl  780 
Phosphate buffer pH 7.4  203 
Distilled water  69 
 
Drug excipients compatibility test 
On comparing the FTIR spectra of pure drug with drug: β-
cyclodextrin, drug: HPMC K15M and drug: EC showed in fig. 2-5, no 
changes were observed in the bands of group present in famotidine 
which indicates the absence of any interaction. Hence it was 
confirmed by the compatibility test that there was no interaction of 
drug with polymers (β-Cyclodextrin, HPMC K15M and EC). 
 
 
Fig. 2: FTIR spectra of pure drug 
 
Evaluation of prepared complex 
Dissolution rate studies 
Prepared complexes were evaluated for drug release in different 
media and compared with pure drug as listed in table 5. Result 
showed that complex enhanced the drug release in all media. In 
distilled water it enhanced the release up to 1.6 folds, in phosphate 
buffer up to 2.04 folds and in 0.1 N HCl up to 2.5. It was indicated 
that complexation of poorly soluble drug was able to enhance the 
solubility of drug. 
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Fig. 3: FTIR spectra of famotidine: β-cyclodextrin 
 
 
Fig. 4: FTIR spectra of famotidine: HPMC K15M 
 
 
Fig. 5: FTIR spectra of famotidine: EC 
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Table 5: % cumulative drug release of drug from complex in different media 
Time (h) % cumulative drug release solvent 
 Distilled water Phosphate buffer 0.1N HCl 
 D1 C1 D2 C2 D3 C3 
0 0 0 0 0 0 0 
0.5 4.94±0.02 9.41±0.22 10.92±0.11 20.94±0.02 13.09±0.12 24.25±0.02 
1 9.09±0.05 15.2±0.01 17.08±0.06 34.97±0.05 32.02±0.22 75.38±0.05 
2 15.12±0.12 20.83±0.30 35.9±0.41 70.57±0.02 74.5±0.05  
4 28.2±0.31 38.38±0.12 46.28±0.21 82.48±0.12   
D = Pure drug, C = Complexed drug, Data expressed, mean±standard deviation (SD, N=3)  
 
Differential scanning calorimetry (DSC) 
The DSC thermograms of famotidine, kneaded complex and beta 
cyclodextrin were presented in fig. 6. Famotidine showed the behaviour 
of non-hygroscopic crystalline drug with a characteristic peak at 166 °C 
(∆H = 331.852 J/g) corresponding to its melting point. Famotidine 
melting point was also observed in the kneaded complex but ∆H value 
(58.64 J/g) was lower than that of the pure drug and the intensity of 
thermal peak of drug was strongly reduced and broadened in the 
kneaded product. This indicates the formation of an inclusion complex. 
 
 
Fig. 6: Comparative DSC thermograms of pure drug (famotidine), pure CD (cyclodextrin) and famotidine-CD complex (kneaded product) 
 
Table 6: Pre-compression parameters 
Formulation code Angle of repose Bulk density (gm/ml) Tapped density (gm/ml) Carr’s Index Hausner’s ratio 
F1 40.67±0.006 0.263±0.005 o.412±0.001 35.32±0.011 1.52±0.001 
F2 41.23±0.012 0.261±0.001 0.423±0.004 38.29±0.032 1.62±0.020 
F3 43.23±0.020 0.288±0.004 0.451±0.005 36.16±.022 1.57±0.022 
F4 40.68±0.011 0.272±0.002 0.431±0.005 36.89±0.024 1.58±0.011 
F5 43.28±0.015 0.265±0.003 0.418±0.002 36.60±0.022 1.57±0.005 
F6 41.23±0.015 0.283±0.002 0.430±0.002 34.18±0.032 1.51±0.024 
F7 40.54±0.032 0.278±0.002 0.438±0.003 36.52±0.013 1.57±0.032 
F8 32.75±0.025 0.261±0.002 0.323±0.003 19.23±0.010 1.24±0.021 
F9 31.72±0.210 0.251±0.002 0.319±0.003 21.31±0.041 1.27±0.022 
F10 34.23±0.022 0.278±0.001 0.356±0.002 21.91±0.062 1.28±0.021 
F11 33.23±0.020 o.267±0.001 0.324±0.001 17.59±0.033 1.21±0.024 
F12 32.22±0.021 0.262±0.001 0.325±0.001 19.38±0.022 1.24±0.011 
F13 31.65±0.021 0.261±0.001 0.322±0.001 19.12±0.212 1.22±0.021 
Data are expressed in mean±standard deviation (SD, N=3)  
 
Evaluation of controlled release tablets 
All batches were evaluated for pre-compression parameters (table 
6) and post-compression parameters (table 7). 
Pre-compression evaluation 
Pre-compression parameters such as angle of repose, bulk density, 
tapped density, flow rate, hausner’s ratio and carr’s index of all 
formulations were reported in table 6 and it was found that granules 
of formulations containing drug-β CD complex showed better flow 
ability rather than the formulations containing pure drug. 
Post-compression evaluation 
All formulations were evaluated for various post-compression 
parameters like thickness of tablets, hardness of tablets, uniformity 
of weight, friability, drug content, swelling index (fig. 7) and 
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percentage drug release and the results were recorded in table7. All 
parameters were complied within the Pharmacopoeial standards. 
Swelling index was found in between 35.92 to 67.33. On comparing 
the formulation containing pure drug (F2, F3, F4, F5, F6 and F7) with 
the formulations containing drug-β-cyclodextrin complex (F8, F9, 
F10, F11, F12 and F13) it was found that tablets containing complex 




Fig. 7: Tablet image before and after swelling 
 













F1 0.48±0.01 1.32±0.01 5.33±0.58 490.67±0.76 0.39±0.02 35.92±0.88 96.65±0.04 
F2 0.48±0.01 1.33±0.01 5.33±0.58 502.64±0.53 0.37±0.02 52.35±0.03 97.55±0.29 
F3 0.48±0.01 1.33±0.01 5.33±0.58 510.53±0.52 0.28±0.02 51.25±0.02 97.92±0.83 
F4 0.48±0.01 1.33±0.01 5.33±0.58 511.47±0.61 0.42±0.03 50.34±0.02 95.72±0.57 
F5 0.48±0.01 1.33±0.01 5.33±0.58 495.72±0.61 0.38±0.02 55.91±0.86 96.49±1.18 
F6 0.48±0.01 1.33±0.01 5.67±0.58 498.12±0.22 0.57±0.04 54.43±0.03 97.74±1.02 
F7 0.48±0.01 1.33±0.01 5.67±0.58 491.51±0.51 0.78±0.01 52.33±0.01 96.42±1.01 
F8 0.48±0.01 1.33±0.01 5.67±0.58 497.82±0.81 0.55±0.04 66.34±0.02 97.89±0.56 
F9 0.48±0.01 1.33±0.01 5.33±0.58 512.21±0.85 0.45±0.04 65.67±0.02 98.40±0.73 
F10 0.48±0.01 1.32±0.01 5.67±0.58 511.12±0.85 0.53±0.04 66.98±0.01 96.42±1.01 
F11 0.48±0.01 1.34±0.01 5.33±0.58 497.67±0.76 0.43±0.03 66.87±0.01 96.48±1.18 
F12 0.48±0.01 1.33±0.01 5.67±0.58 500.93±1.01 0.38±0.02 67.33±0.58 98.78±0.77 
F13 0.48±0.01 1.32±0.01 5.67±0.58 497.56±0.59 0.76±0.05 65.45±0.02 96.80±1.60 
Data are expressed in mean±standard deviation (SD, N=3) 
 
In vitro dissolution test 
The release profile of famotidine controlled release matrix tablets from 
different batches were illustrated in table 8 and fig. 8. Formulation F7 
containing 62% HPMCK15M and 38% EC showed 88.02% release within 
12 h of dissolution study and formulation F13 containing complexed 
drug with same polymer blend ratio showed 98.92% release that was 
controlled up to 12 h.  
This may be due to a more rigid complex formed by hydrophilic 
polymers (HPMCK15M) when used in much concentrations along with 
the presence of EC which helped in retaining the drug in the matrix and 
did not allowed rapid diffusion of soluble drug from the matrix. Hence 
the F13 formulation was the best formulation based on controlling the 
release rate for 12 h and cyclodextrin can be used as a better tool for 




Fig. 8: % drug release±SD of selected formulations at different time intervals 
Ain et al. 
Int J App Pharm, Vol 9, Issue 4, 2017, 38-46 
45 




F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 F13 





































































































































































































Data are expressed in mean±standard deviation (SD, N=3) 
 
Drug release kinetic study 
The in vitro release pattern of the selected formulation was analyzed 
by fitting the dissolution data in to various kinetic models. From 
which it was concluded that formulation F13 followed zero order 
release (table 9) and the release mechanism was predominant 
matrix swelling and erosion. Therefore the drug release from 
prepared tablet is controlled by more than one process i.e. swelling 
of polymer followed by drug diffusion through the swelled polymer 
and slow erosion of the tablet. A correlation data showed that 
complex of drug with polymer blend (HPMC K15M and EC) was 
found to be more significant. 
 
Table 9: Drug release kinetic study 
Formulation Mathematical models 
 r2 n 
Zero order First order Higuchi model Peppas model Peppas 
F7 0.8942 0.9562 0.8184 0.9242 0.8131 
F13 0.9840 0.8024 0.8574 0.9421 0.8865 
 
Scanning electron microscopy (SEM) 
Scanning electron microscopic study of the selected formulation was 
also carried for both conditions, normal tablet and swollen tablet 
(fig. 9). On observing the both images it was concluded that tablet 
matrix absorbed the solvent and formed a jelly like structure. As 
there was no jelly like structure was found in SEM image of normal 
tablet. It was confirmed that the drug release from the matrix tablet 
via swollen followed by erosion method. 
Stability study 
Selected formulations (F7and F13 showed in fig. 10) were kept for 
90 d in stability chamber under controlled temperature and 
moisture. Temperature was kept 40±5 °C and humidity was 
maintained at 70±2 %. Samples were withdrawn at 0, 30 and 90 d 
interval and evaluated for various parameters as listed in table 10. It 
was indicated that there were no significant changes observed in 
drug content and absorption maxima at the end of three mo period. 
 
 
Fig. 9: Scanning electron microscopy (SEM) of normal and swelled tablet 
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Fig. 10: Physical appearance of selected formulation 
 
Table 10: Stability data of selected formulations 













F7 No change 266 nm 96.49 % No change 266 nm 95.48 % No change 266 nm 95.20 % 
F13 No change 26 6 nm 98.78 % No change 266 nm 96.72 % No change 266 nm 96.14 % 
 
CONCLUSION 
Results of the present study was concluded that the drug: β-
cyclodextrin complex would be a suitable candidate for preparing 
controlled release tablets of famotidine to improve drug solubility, 
flow properties and compressibility. Release studies indicated that 
polymer blend (62 % HPMC and 38 % EC) based matrix tablets with 
drug and drug: β-cyclodextrin was able to control the release of 
famotidine up to 12 h. Swelling with erosion might be the 
mechanism for drug release and the correlation data showed that 
F13 formulation followed zero order release was found to be more 
significant. Thus the complex used in matrix tablet is a promising 
approach to achieve appropriate controlled release dosage form. 
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